Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Toyobo's Sales to Top ¥400 Bil. in FY2015 Driven by Life Science Business
March 15, 2010
- Korosho Starts Hearing Major Chain Pharmacy Operators
March 15, 2010
- EFPIA Japan to Work to Eliminate Drug Lag
March 15, 2010
- Astellas Withdraws Application for Diabetic Incipient Nephropathy for Micardis
March 15, 2010
- Teijin Licenses SB623 from SanBio
March 15, 2010
- Korosho to Prepare for 2nd Round of Screening by GRU
March 15, 2010
- 2009 Sales of Ethical Drugs Up 7.2% to ¥8,851.6 Bil.: IMS Japan
March 15, 2010
- Takeda to Initiate PIII Trials for Lu AA21004, Lu AA24530 in the US
March 15, 2010
- Banyu, Santen to Copromote Cosopt
March 15, 2010
- Sanofi-aventis Begins Post-marketing Program on Apidra
March 15, 2010
- NDA for Cancer Pain Killer KW-2246 Submitted in Japan: Kyowa Kirin
March 8, 2010
- Dr Haranaka Opens Campaign Office for JMA Election
March 8, 2010
- Takeda Loses Sole Lead Among Admired Companies
March 8, 2010
- Novartis, Ono Apply for Rivastigmine Patch for AD in Japan
March 8, 2010
- NHI Program's Deficit Decreased in FY2008
March 8, 2010
- Eisai Launches Revovir in the Philippines
March 8, 2010
- Janssen Applies for Galantamine for AD in Japan
March 8, 2010
- New HIV-Infected Persons Down to 1,008 in 2009
March 8, 2010
- Daiichi Sankyo to Educate People about Vaccines
March 8, 2010
- Korosho's Study Group Issues Preliminary Report on Regenerative Cell Therapy
March 8, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…